Testosterone prevents protein loss via the hepatic urea cycle in human

Teresa Lam1,2, Anne Poljak3, Mark McLean1,2, Neha Bahl1,4, Ken K Y Ho4,5 and Vita Birzniece1,2,4,6

1School of Medicine, Western Sydney University, Penrith, New South Wales, Australia, 2Department of Diabetes and Endocrinology, Blacktown Hospital, Blacktown, New South Wales, Australia, 3Bioanalytical Mass Spectrometry Facility and School of Medical Sciences, University of New South Wales, New South Wales, Australia, 4Garvan Institute of Medical Research, Sydney, New South Wales, Australia, 5Centres of Health Research, Princess Alexandra Hospital, Brisbane, Queensland, Australia, and 6School of Medicine, University of New South Wales, New South Wales, Australia

Abstract

Context: The urea cycle is a rate-limiting step for amino acid nitrogen elimination. The rate of urea synthesis is a true indicator of whole-body protein catabolism. Testosterone reduces protein and nitrogen loss. The effect of testosterone on hepatic urea synthesis in humans has not been studied.

Objective: To determine whether testosterone reduces hepatic urea production.

Design: An open-label study.

Patients and intervention: Eight hypogonadal men were studied at baseline, and after two weeks of transdermal testosterone replacement (Testogel, 100 mg/day).

Main outcomes measures: The rate of hepatic urea synthesis was measured by the urea turnover technique using stable isotope methodology, with 15N2-urea as tracer. Whole-body leucine turnover was measured, from which leucine rate of appearance (LRa), an index of protein breakdown and leucine oxidation (Lox), a measure of irreversible protein loss, were calculated.

Results: Testosterone administration significantly reduced the rate of hepatic urea production (from 544.4 ± 71.8 to 431.7 ± 68.3 µmol/min; \( P < 0.01 \)), which was paralleled by a significant reduction in serum urea concentration. Testosterone treatment significantly reduced net protein loss, as measured by percent Lox/LRa, by 19.3 ± 5.8% (\( P < 0.05 \)). There was a positive association between Lox and hepatic urea production at baseline (\( r^2 = 0.60, P < 0.05 \)) and after testosterone administration (\( r^2 = 0.59, P < 0.05 \)).

Conclusion: Testosterone replacement reduces protein loss and hepatic urea synthesis. We conclude that testosterone regulates whole-body protein metabolism by suppressing the urea cycle.

Introduction

Testosterone increases muscle mass and strength and improves physical function in men (1). Declining levels of testosterone are associated with the development of sarcopenia and frailty in men, and testosterone replacement in hypogonadal men increases muscle mass and strength (2, 3). However, tissue-specific biochemical mechanisms of androgen action are not fully understood.

Testosterone regulates amino acid availability, facilitating reutilization and increasing muscle protein anabolism (4, 5). We have previously shown that the whole-body protein accretion effects of testosterone are mediated through the liver (6, 7). In hypogonadal men, selective exposure of the liver to testosterone by oral administration reduces protein oxidation, a hallmark of catabolism.
This effect is indistinguishable to that of systemic (transdermal) testosterone administration. Thus, the liver is the primary site underpinning the anti-catabolic effect of testosterone. However, the intrahepatic biochemical pathways mediating the protein anabolic action of testosterone are unclear (8, 9).

Protein mass is constantly turning over in a dynamic process of breakdown and synthesis. Amino acids, derived from proteolysis, are either oxidized and irreversibly lost or resynthesized into protein. The liver is a major site of protein metabolism and degradation of amino acids, which is controlled by the urea cycle. Surplus α-amino nitrogen derived from degradation of amino acids enters the urea cycle as ammonia and is converted to urea in hepatocytes and subsequently eliminated. This represents an irreversible loss of protein nitrogen (10). Hormones such as glucagon, glucocorticoids and growth hormone regulate urea cycle enzymes in the liver (11, 12). Early studies in rats also observed an inhibitory effect of testosterone on the arginine synthetase system, a key component of the urea cycle (13). Although it has since been demonstrated that testosterone increases nitrogen retention (14), evidence that testosterone suppresses urea production in humans is lacking.

The aim of this study was to determine in humans whether testosterone inhibits hepatic urea production. We employed stable isotope studies to investigate the effects of systemic testosterone administration on hepatic urea production in hypogonadal men. The leucine turnover technique was undertaken simultaneously to confirm that testosterone enhanced whole-body protein anabolism.

Subjects and methods

Subjects

Eight hypogonadal men were recruited from Endocrine Outpatients Clinics in Western Sydney, Australia. Inclusion criteria included males aged between 18 and 75 years with diagnosed primary or secondary hypogonadism, and adequate replacement of other hormones in the case of hypopituitarism. Exclusion criteria included patients with diabetes mellitus, malignancies, chronic renal or hepatic illnesses or taking medications known to interfere with the endocrine system. Out of eight patients, one had Klinefelter Syndrome, four had pituitary adenomas with hypogonadism and three had hypogonadism of unknown cause.

This study was approved by the Western Sydney Local Heath District Human Research Committee. The study was conducted in accordance with the principles of the Declaration of Helsinki. All participants gave written informed consent. The study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN 1261000577415).

Study design

In an open-label study, eight hypogonadal subjects were studied at baseline, and after two weeks of testosterone replacement by the transdermal route (Testogel; Besins Healthcare Australia Pty Ltd, 10mg/g), administered at a dose of 100mg/day. The main endpoint measurement was rate of hepatic urea synthesis. Other endpoint measurements included (1) whole-body leucine rate of appearance (LRa) and oxidation (Lox), which are indices of whole protein breakdown and oxidative loss, respectively, (2) energy expenditure, (3) body composition and (4) other biochemical markers of intervention, including serum levels of testosterone, urea, sex hormone-binding globulin (SHBG) and insulin-like growth factor. All participants were instructed to follow their usual diet and physical activity. Participants were studied after an overnight fast in the Blacktown Clinical School and Research Centre, Australia. At each visit, study blood samples were collected and placed on ice, and plasma and serum were separated and stored at −80°C until analysis.

Methods

Protein turnover

The leucine turnover technique was used to measure whole-body protein metabolism. This method is based on the principle of steady-state kinetics whereby the rate of appearance of a substrate equals its rate of disposal. Leucine is either oxidized or re-incorporated into protein, and the fractional partitioning between these two pathways of disposal is determined from the fraction of infused isotope that appears in breath. The LRa and Lox were calculated as previously described (15). A-Ketoisocaproic acid (KIC) is formed when leucine undergoes transamination. It is used as a surrogate marker of leucine as it more accurately reflects the intracellular environment (16).

A 0.014mg/kg priming dose of NaH13CO3 was given after an overnight fast, followed by a primed constant 3-h infusion of 1-[13C]leucine (prime 0.5mg/kg, infusion 0.5mg/kg/h) (17, 18). NaH13CO3 and 1-[13C]leucine were obtained from Cambridge Isotope Laboratories (Woburn, MA). On each visit, blood and breath samples were
collected before (~10 and 0min) and during (140, 160 and 180min) the leucine infusion. Blood was placed on ice, and plasma was separated and stored at ~80°C. As described by Nissen et al., KIC was extracted from plasma (19). Plasma KIC enrichment with 13C was measured by gas chromatography–mass spectrometry (GCMS) (MSD 5971A, model 5890, Hewlett-Packard Co., Palo Alto, CA, USA). CO2 enrichment with 13C in breath samples was measured at the University of Surrey, United Kingdom, on a Delta Plus XP isotope ratio mass spectrometer fitted with a Gas Bench II inlet system (Thermo Fisher Scientific). Based on previous experiences, our coefficients of variation (CV) for LRa and Lox are 3.5 and 6.1%, respectively (20).

Urea synthesis

The rate of urea synthesis was measured by the urea turnover technique using stable isotope methodology, with 15N2-Urea as tracer. Surplus α-amino nitrogen derived from protein degradation enters the hepatic urea cycle as ammonia and is converted to urea. Thus, the rate of urea synthesis is a true indicator of net protein catabolism. Previously functional hepatic nitrogen clearance studies used blood α-amino nitrogen concentrations and urinary urea-N excretion during infusion of amino acids (21). Our technique is based on an earlier protocol, which employs stable isotopes in the measurement of urea synthesis (22), offering time and sensitivity advantage.

After an overnight fast, a priming dose of 15N2-Urea (3.4 mg/kg; Cambridge Isotope Laboratories, Andover, MA, USA) was given, followed by a continuous infusion of the tracer at 0.34 mg/kg/h for 4 h. On each visit, blood samples were collected before (~10 and 0min) and during (120, 180, 210 and 240 min) the primed infusion, when steady state was reached. Plasma samples were collected into chilled tubes, separated immediately and stored at ~80°C until analysis. [13C,15N2]-Urea was added to plasma samples as an internal control, and samples were prepared for analysis as previously described (23), with modifications. Briefly, plasma samples were treated with ethanol for one hour at ~20°C to precipitate proteins. The labeled and non-labeled urea in the samples was then converted to 2-hydroxypyrimidine using malonaldehyde bis(dimethyl acetal) and HCl during the one-hour incubation. The samples were evaporated to dryness in a Speed Vac concentrator for at least three hours, and reacted with MSTFA (N-methyl-N-(trimethyl-silyl) trifluoroacetamide) to form a trimethylsilyl derivative of 2-hydroxypyrimidine. Enrichments of [15N2] and [15N4]-urea were determined by GC–MS (MSD 5971A, model 5890, Hewlett-Packard Co.). Enrichments were expressed as tracer-to-tracee molar ratios and calculated from the deconvoluted enrichment peak ratios (m/z 155/153). Rate of hepatic urea production is an inverse measure of isotopic enrichment of [15N2]-urea in blood and was calculated as a product of the rate of urea infusion and the tracer-to-tracee ratio. In our hands, day-to-day variation in urea production is 5.5%, inter-assay CV 3.5% and intra-assay CV 1.8%, assessed in four healthy men on two occasions one-week apart.

Energy expenditure

Whole-body energy expenditure and substrate oxidation were measured by indirect calorimetry using an open-circuit ventilated hood system (ParvoMedics, Sandy, UT, USA), calibrated against standard gases before each study. The participants rested in a supine position for at least 30min and a clear plastic hood was placed over their heads for a period of 20min. Two measurements were taken and averaged.

Body composition

Fat mass (FM), lean body mass (LBM) and extracellular water (ECW) were assessed using Bioelectrical Impedance Spectroscopy (BIS; SFB7 analyzer, ImpediMed Ltd, Qld, Australia) (24). After 20min of rest, two measurements were taken in the supine position, and the average was taken. Body cell mass (BCM), an estimate of muscle mass, was calculated by subtracting ECW from the LBM.

Assays

All samples for any individual were measured in the same assay run for each analyte. Concentrations of serum SHBG, testosterone and total PSA were measured by an electrochemiluminescence immunoassay (ECLIA) using a commercial assay kit (Roche Diagnostics). The CV for SHBG at 45.7 nmol/L was 2.1% and the CV for total testosterone at 0.087 nmol/L was 2.8%. The CV for total PSA at 0.3 ng/mL was 2.4%. Serum urea and albumin were measured photometrically. The CV for urea at 7.2 mmol/L was 1.2%, and albumin at 49.6 g/L was 0.4%. The concentration of serum insulin was measured by chemiluminescent microparticle immunoassay (CMIA) and the CV at 55.08 μU/mL was 2.5%. Serum creatinine was measured by a kinetic calorimetric assay and the CV at
72.9 μmol/L was 2.3%. Serum IGF-I levels were measured by RIA after acid ethanol extraction, and the CVs for IGF-I were 8.3% at 14.7 nmol/L and 7.4% at 28.6 nmol/L.

Statistical analysis

The treatment effects of testosterone on urea synthesis and protein turnover were assessed using paired t tests. Results are expressed as mean ± S.E.M., and a P value < 0.05 was considered to be significant. Linear regression analysis was used to correlate changes in urea synthesis with other endpoint measures. A linear mixed-effect model was used to determine the effect of changes in serum testosterone, LBM, BCM and IGF-1 on urea synthesis. Statistical analysis was undertaken using the statistical software package SPSS statistics, v22 (IBM Corporation) and RStudio (Boston, MA, USA).

Results

The mean age of participants was 49.1 ± 4.9 years. Their clinical, hormonal and metabolic characteristics at baseline, and after two weeks of transdermal testosterone therapy, are shown in Table 1. Administration of 100mg/day of transdermal testosterone for two weeks increased serum levels of testosterone into the normal range (Fig. 1).

Urea and protein turnover

The baseline rate of hepatic urea synthesis was 544.4 ± 71.8 µmol/min. After testosterone administration for two weeks, urea production fell significantly by

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical, hormonal and metabolic measures at baseline and after two weeks of transdermal testosterone treatment. Data are presented as mean ± S.E.M.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>99.9 ± 14</td>
</tr>
<tr>
<td>BMI</td>
<td>31.5 ± 3.9</td>
</tr>
<tr>
<td>Lean body mass (% weight)</td>
<td>69.1 ± 2.1</td>
</tr>
<tr>
<td>Body cell mass (kg)</td>
<td>46.0 ± 5.6</td>
</tr>
<tr>
<td>Extracellular water (L)</td>
<td>22.0 ± 3.0</td>
</tr>
<tr>
<td>SHBG (nmol/L)</td>
<td>29.6 ± 6.4</td>
</tr>
<tr>
<td>IGF-1 (nmol/L)</td>
<td>17.6 ± 2.9</td>
</tr>
<tr>
<td>Urea (mmol/L)</td>
<td>6.0 ± 0.5</td>
</tr>
<tr>
<td>Creatinine (µmol/L)</td>
<td>77.9 ± 3.3</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>41.4 ± 0.9</td>
</tr>
<tr>
<td>ALT (IU/L)</td>
<td>28.8 ± 2.1</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>27.6 ± 2.7</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>5.6 ± 0.3</td>
</tr>
<tr>
<td>Insulin (IU/L)</td>
<td>59.9 ± 13.0</td>
</tr>
<tr>
<td>PSA (ng/mL)</td>
<td>0.80 ± 0.3</td>
</tr>
<tr>
<td>REE (kcal/day)</td>
<td>1717.6 ± 135.5</td>
</tr>
<tr>
<td>Fox (mg/min)</td>
<td>53.2 ± 5.5</td>
</tr>
<tr>
<td>Cox (mg/min)</td>
<td>116.6 ± 13.3</td>
</tr>
</tbody>
</table>

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Cox, carbohydrate oxidation; Fox, fat oxidation; IGF-1, insulin-like growth factor; PSA, prostate-specific antigen; REE, resting energy expenditure; SHBG, sex-hormone-binding globulin.
Testosterone reduces urea production

T Lam and others

21 ± 5% (P < 0.01; Fig. 2) accompanied by a fall (P < 0.01) in serum urea concentration (Table 1).

Testosterone administration did not significantly affect LRa, a measure of protein turnover (Table 2). Leucine oxidized as a proportion of LRa (percent Lox/LRa), which represents the proportion of amino acids that are irreversibly lost when adjusted for changes in protein turnover, was significantly reduced by 19.3 ± 5.8% (P < 0.05) after testosterone administration.

Other endpoint measures

On average, the weight of participants increased by 1.1 ± 0.4 kg (Table 1). Two weeks of testosterone administration did not significantly change any of the body composition parameters. After two weeks of testosterone administration, there was a significant increase in resting energy expenditure by 76.2 ± 26.4 kcal/day (P < 0.05). There were no significant changes in the rates of fat or carbohydrate oxidation. There were no significant changes in any of the measured endocrine markers, including serum levels of SHBG, IGF-1, glucose or insulin. Similarly, testosterone did not significantly change levels of liver transaminases (AST and ALT), albumin, creatinine or prostate-specific antigen (Table 1).

Association between urea synthesis and other endpoint measurements

The rate of hepatic urea production was significantly correlated with net Lox, a maker of irreversible loss of protein before (r² = 0.60, P < 0.05; Fig. 3A) and after testosterone replacement (r² = 0.59, P < 0.05). The slopes of the relationship between urea production and Lox were similar before and during the treatment (P = 0.34). Hepatic urea production significantly correlated with serum urea concentration at baseline and during testosterone administration (P < 0.05; Fig. 3B). The reduction in hepatic urea synthesis could not be predicted by changes in serum testosterone, LBM, BCM or IGF-1 by a linear mixed-effects model.

Discussion

This study is the first to investigate the effects of testosterone on hepatic urea production in humans. We show that testosterone replacement significantly reduces hepatic urea production in hypogonadal men. This occurs in parallel with a significant fall in leucine oxidation, an index of irreversible loss of whole-body protein. We provide evidence that testosterone induction of protein anabolism in humans is most likely mediated by inhibition of the hepatic urea cycle, thereby conserving amino acids for protein synthesis (Fig. 4).

Hormones that cause catabolism, such as glucocorticoids and glucagon, stimulate urea synthesis, as reflected in an enhancement of functional hepatic nitrogen clearance (25). At the in vitro level, glucocorticoids increase gene expression of enzymes promoting urea synthesis (12). Hepatic glucocorticoid receptors control urea cycle function via transcriptional activation of the
Arginase 1 gene (26). Similarly, treatment with glucagon upregulates enzymes of the urea cycle in cultured rat hepatocytes such as carbamoyl phosphate synthetase, arginosuccinate and arginase (12). The reverse occurred when rats were treated with growth hormone, an anabolic hormone (11). However, the effect of testosterone is not established, and the evidence from animal studies is contradictory. In ovariectomized female rats, testosterone treatment for ten days significantly reduced arginine synthetase activity, a key enzymatic component of the urea cycle (27). However, intraperitoneal injection of testosterone into female rats has also been shown to increase liver arginase activity (28). Thus, early work in female rats report discordant effects of testosterone on urea cycle enzyme activity. Although it is long established that testosterone is nitrogen sparing (14), biochemical evidence that testosterone inhibits the urea cycle has been lacking. We here provide unequivocal evidence for a direct effect of testosterone on the hepatic urea cycle in humans. We found that restoring testosterone levels into the normal range reduced hepatic urea production by approximately 20% in hypogonadal men.

Androgens increase muscle mass and strength (29). Although androgens regulate muscle protein economy indirectly through the urea cycle, they also act directly on muscle stimulating myoblast growth and differentiation, inducing muscle fiber hypertrophy (30). The extent to which the indirect and direct actions of androgens contribute to muscle mass has been a subject of great interest and explored by utilizing muscle-specific AR-knockout models. These models provide evidence of cell type-specific effects of AR activation in the regulation of muscle anabolism. Studies in myocyte-specific AR-knockout (mARKO) mice show surprising preservation of skeletal muscle mass, with muscle loss restricted only to the highly androgen-sensitive levator ani muscle (31, 32). Conversely, studies in mARKO mice on the effects of orchidectomy (31), and global AR-knockout mice, show a significant but selective reduction in the mass of hind limb skeletal muscles (33). This indicates that androgen receptor activation purely in myocytes is not sufficient to induce muscle anabolism. It has been proposed that androgen effects on muscle may be mediated through other cell types, such as satellite cells, myofibroblasts and motor neurons (34, 35), via non-genomic pathways (36), or through testosterone aromatization to estradiol (37). Thus, the regulation of muscle mass by androgens is complex, involves direct, indirect and paracrine mechanisms. We now add an additional component to this system by demonstrating that testosterone action on the liver reduces loss of amino acid nitrogen, potentially increasing the pool available for muscle anabolism.

There is a linear relationship between the hepatic urea synthesis rate and the blood amino acid concentration. Therefore, a fall in amino acid concentration in the blood (due to e.g. decrease in protein breakdown in the muscle) may reduce the rate of urea production. However, this did not occur, as we provide evidence that protein breakdown (LRa) was unaffected by testosterone replacement. Thus, it is highly unlikely that the reduced urea production in our study would have resulted from a reduction in amino acid availability. Nevertheless, it would be of interest to measure the amino nitrogen concentrations. Previous research, however, reports increase in amino acid plasma concentration during testosterone replacement (38). As amino acid availability in blood is expected to increase with testosterone administration, this would result in an increase in urea production. However, the reverse was found in our study. Therefore, this provides strong evidence that testosterone acts on the liver directly to reduce urea production.

The leucine and urea turnover techniques are established methods for quantifying whole-body protein metabolism. Both methods quantify the oxidative metabolism of amino acids by tracking the disposal of labeled molecular constituents of amino acid. The leucine turnover technique tracks the metabolic fate of the carbon moieties of amino acids, providing a measure of whole-body protein oxidative loss. The urea turnover
In summary, we provide the first evidence that testosterone stimulates protein anabolism by acting on the liver to reduce irreversible nitrogen loss through the urea cycle. These findings are highly significant as may lead to the future use of liver-targeted testosterone therapy as a potential intervention in the treatment of sarcopenia, without the adverse effects of systemic testosterone.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality in this study.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author contribution statement
Dr Teresa Lam assisted with study visit conduct, data analysis and wrote the manuscript; Dr Anne Poljak developed stable isotope method, assisted with sample and data analysis and contributed to manuscript preparation; Prof Mark McLean developed research concept, recruited patients and contributed to manuscript preparation; Dr Neha Bahl developed assay method, assisted with sample analysis and contributed to manuscript preparation; Prof Ken Ho developed research concept and contributed to manuscript preparation; Dr Vita Bizniece developed research concept, performed study visits, assisted with data analysis and contributed to manuscript preparation.

Acknowledgements
The authors would like to acknowledge research nurse Meredith Jamieson for clinical assistance, Dr David Chipps, Dr Jane Holmes-Walker, Dr Naswirin Moin and Dr Tien-Ming Hng for assistance with patient recruitment and Prof Margot Umpleby and Dr Nicola Jackson from University of Surrey, UK, for assistance with mass spectrometry. They also thank Surya Sutanto and the Endocrinology Lab, Royal Prince Alfred Hospital, Sydney, Australia, for providing laboratory assistance and Prof. Glenn Stone from Western Sydney University, Australia, for providing statistical assistance.

References
Testosterone reduces urea production


Received 18 October 2016
Revised version received 5 January 2017
Accepted 25 January 2017